Table 4.

Hazard Ratio (low vs. high or positive vs. negative) in Univariate and Multivariable Models

Model	Predictor(s)d	N	Progression-Free Survival			Overall Survival
			HRa	(95% CI)	P	HRa	(95% CI)	P
Univariate
	Tumor HPV by ISH	29	0.28	(0.08–1.00)	0.05	0.09	(0.01–0.71)	0.02
	Tumor P16 by IHC	30	1.71	(0.55–5.3)	0.36	2.2	(0.61–7.93)	0.23
	Tumor EGFR by IHC	31	0.27	(0.09–0.86)	0.03	0.72	(0.26–2.03)	0.53
	Tumor EGFR copy number by ISH	26	1.31	(0.45–3.82)	0.62	1.45	(0.47–4.50)	0.52
	Tumor Met by IHC	30	0.64	(0.24–1.73)	0.38	0.71	(0.25–2.06)	0.53
	Tumor ERCC1 by AQUA	32	0.55	(0.17–1.80)	0.32	0.87	(0.30–2.79)	0.87
	Tumor ERCC1 by IHC	27	0.61	(0.22–1.69)	0.34	0.61	(0.22–1.73)	0.36
	Tumor XPF by AQUA	31	0.69	(0.26–1.84)	0.45	0.41	(0.14–1.21)	0.11
	Tumor XPF by IHC	25	0.52	(0.16–1.64)	0.26	0.99	(0.32–3.08)	0.99
	Plasma EGFR	27	0.35	(0.09–1.33)	0.12	0.79	(0.22–2.79)	0.71
	Plasma Amphiregulin	27	0.46	(0.14–1.50)	0.19	0.45	(0.13–1.59)	0.22
	Plasma TGF-alpha	27	0.62	(0.19–2.04)	0.43	0.57	(0.16–2.01)	0.38
	Plasma EGF	27	0.35	(0.09–1.31)	0.12	0.66	(0.19–2.34)	0.52
	Plasma Epiregulinb	27	1.89	(0.24–14.78)	0.54	-	-	-
	Plasma HGF	27	0.81	(0.25–2.68)	0.73	0.33	(0.09–1.29)	0.11
	Plasma IL-8	27	0.99	(0.30–3.27)	0.99	1.13	(0.33–3.92)	0.84
	Plasma IL-6	27	0.67	(0.20–2.19)	0.50	0.34	(0.09–1.32)	0.12
	Plasma VEGF	27	1.02	(0.31–3.34)	0.98	0.99	(0.29–3.41)	0.98
Multivariablec
	Tumor HPV Status	29	0.31	(0.06–1.43)	0.11	0.06	(0.01–0.80)	0.03

^aLow-expression level vs. high-expression level or positive status vs. negative status, depending on the marker.

^bNo statistic was reported for OS because no death event was observed in the high expression group.

^cMultivariable model adjusted for age, sex, race, performance status, weight loss prior 6 months (<5% vs. ≥5%), tumor primary site (oropharynx vs. non-oropharynx), smoking history (ever vs. never).

^dImmunohistochemical staining (IHC), in situ hybridization (ISH).